GlassScriptPhysician profile
Jamuna D Raju
NPI 1922290873
$6,372.81
in general payments reported to CMS, 2019-2025
20 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $137 · 2021: $527 · 2022: $1,028 · 2023: $1,491 · 2024: $992 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.04 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.90 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $887.02 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $708.71 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $667.85 | 2019-2025 | Rexulti |
| Alkermes, INC. | $640.53 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $536.76 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $393.16 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $386.63 | 2019-2022 | |
| Bausch Health US, LLC | $305.24 | 2019-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $249.13 | 2019-2020 | |
| Axsome Therapeutics, INC. | $205.40 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $90.59 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $69.15 | 2024-2025 | Ingrezza |
| Novo Nordisk INC | $48.31 | 2023 | Wegovy |
| Jazz Pharmaceuticals INC. | $40.97 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $19.06 | 2021 | |
| Orexo US, INC. | $17.11 | 2023 | Zubsolv |
| Alfasigma USA, INC. | $16.47 | 2020 | |
| Currax Pharmaceuticals LLC | $13.76 | 2022 | |
| Indivior INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamuna Raju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.